SK79298A3 - Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen - Google Patents

Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen Download PDF

Info

Publication number: SK79298A3
Authority: SK; Slovakia
Prior art keywords: gestagen; dose; daily; days; administration
Prior art date: 1995-12-23

Application number

SK792-98A

Other languages

English (en)

Slovak (sk)

Inventor

Jan Endrikat

Bernd Dusterberg

Pia Reilhac

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-23

Filing date

1996-12-20

Publication date

2000-06-12

1996-12-20 Application filed by Schering Ag filed Critical Schering Ag

2000-06-12 Publication of SK79298A3 publication Critical patent/SK79298A3/sk

Links

239000000583 progesterone congener Substances 0.000 title claims abstract description 61
239000000262 estrogen Substances 0.000 title claims abstract description 34
239000003433 contraceptive agent Substances 0.000 title claims abstract description 19
230000002254 contraceptive effect Effects 0.000 title claims abstract description 16
238000000034 method Methods 0.000 title abstract description 13
241000124008 Mammalia Species 0.000 title abstract description 5
230000008569 process Effects 0.000 title abstract description 3
229940011871 estrogen Drugs 0.000 claims description 32
229960004400 levonorgestrel Drugs 0.000 claims description 16
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 15
229960005352 gestodene Drugs 0.000 claims description 14
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 14
230000016087 ovulation Effects 0.000 claims description 14
230000002401 inhibitory effect Effects 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 6
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 4
229960004845 drospirenone Drugs 0.000 claims description 4
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 4
229940053934 norethindrone Drugs 0.000 claims description 3
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 3
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 2
-1 chlormadinoacetate Chemical compound 0.000 claims description 2
229960000978 cyproterone acetate Drugs 0.000 claims description 2
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 2
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 2
229960003309 dienogest Drugs 0.000 claims description 2
229960001652 norethindrone acetate Drugs 0.000 claims description 2
229960003387 progesterone Drugs 0.000 claims description 2
239000000186 progesterone Substances 0.000 claims description 2
238000002360 preparation method Methods 0.000 description 27
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 13
229930182833 estradiol Natural products 0.000 description 13
229960005309 estradiol Drugs 0.000 description 13
230000000740 bleeding effect Effects 0.000 description 9
230000003054 hormonal effect Effects 0.000 description 6
229940124558 contraceptive agent Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000004696 endometrium Anatomy 0.000 description 4
230000008901 benefit Effects 0.000 description 3
239000003539 oral contraceptive agent Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 2
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000035558 fertility Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000002175 menstrual effect Effects 0.000 description 2
229940127234 oral contraceptive Drugs 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
239000006213 vaginal ring Substances 0.000 description 2
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
150000000319 19-nortestosterones Chemical class 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
206010002659 Anovulatory cycle Diseases 0.000 description 1
235000003092 Artemisia dracunculus Nutrition 0.000 description 1
240000001851 Artemisia dracunculus Species 0.000 description 1
241000252095 Congridae Species 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960004976 desogestrel Drugs 0.000 description 1
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000006651 lactation Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229960001910 lynestrenol Drugs 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940100640 transdermal system Drugs 0.000 description 1
239000000029 vaginal gel Substances 0.000 description 1
229940044953 vaginal ring Drugs 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

SK792-98A 1995-12-23 1996-12-20 Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen SK79298A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19549264A DE19549264A1 (de)	1995-12-23	1995-12-23	Verfahren und Kit zur Kontrazeption
PCT/DE1996/002486 WO1997023228A2 (de)	1995-12-23	1996-12-20	Verfahren und kit zur kontrazeption bei weiblichen säugern, bestehend aus einer kombination von gestagen und estrogen

Publications (1)

Publication Number	Publication Date
SK79298A3 true SK79298A3 (en)	2000-06-12

Family

ID=7781724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK792-98A SK79298A3 (en)	1995-12-23	1996-12-20	Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen

Country Status (23)

Country	Link
US (1)	US6995149B1 (cs)
EP (1)	EP0868188B1 (cs)
JP (1)	JP2000502108A (cs)
KR (1)	KR19990076685A (cs)
AT (1)	ATE244567T1 (cs)
AU (1)	AU716249B2 (cs)
BR (1)	BR9612207A (cs)
CA (1)	CA2241192A1 (cs)
CZ (1)	CZ291743B6 (cs)
DE (2)	DE19549264A1 (cs)
DK (1)	DK0868188T3 (cs)
ES (1)	ES2202498T3 (cs)
HU (1)	HUP9901662A3 (cs)
IL (1)	IL124472A (cs)
IS (1)	IS4753A (cs)
MX (1)	MX9804395A (cs)
NO (1)	NO982902L (cs)
NZ (1)	NZ330741A (cs)
PL (1)	PL187180B1 (cs)
PT (1)	PT868188E (cs)
SK (1)	SK79298A3 (cs)
UA (1)	UA59356C2 (cs)
WO (1)	WO1997023228A2 (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2754179B1 (fr) *	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr)	1999-10-25	2001-05-03	Laboratoire Theramex	Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
AU759925B2 (en) *	1997-09-12	2003-05-01	Wyeth	Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin
EP1535618A1 (en) *	2003-11-26	2005-06-01	Schering Aktiengesellschaft	Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102008036825A1 (de) *	2008-08-05	2010-02-11	Aicuris Gmbh & Co. Kg	Schwangerschaftsvermeidung durch Gestagene
CA2740004A1 (en) *	2008-10-08	2010-04-15	Agile Therapeutics, Inc.	Transdermal delivery
US9198919B2 (en) *	2008-10-08	2015-12-01	Agile Therapeutics, Inc.	Contraceptive transdermal delivery of hormones
ES2734510T3 (es) *	2008-10-08	2019-12-10	Agile Therapeutics Inc	Administración transdérmica
EP2410859A4 (en) *	2009-03-27	2013-03-13	Agile Therapeutics Inc	TRANSDERMAL ADMINISTRATION
JP5954736B2 (ja) *	2011-01-12	2016-07-20	国立大学法人宮崎大学	難治性炎症性腸疾患の予防又は治療方法
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0368373A1 (en)	1988-10-13	1990-05-16	Akzo Nobel N.V.	Multi-phase contraceptive preparation
NL9301562A (nl) *	1993-09-09	1995-04-03	Saturnus Ag	Preparaat voor substitutietherapie.
CN1188189C (zh) *	1995-06-07	2005-02-09	奥瑟－麦内尔制药公司	基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US6139873A (en) *	1996-07-10	2000-10-31	Cedars-Sinai Medical Center	Combined pharmaceutical estrogen-androgen-progestin
US5770226A (en) *	1996-07-10	1998-06-23	Wake Forest University	Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US5888543A (en) *	1996-07-26	1999-03-30	American Home Products Corporation	Oral contraceptives
US6479475B1 (en) *	1996-07-26	2002-11-12	Wyeth	Oral contraceptive
FR2754179B1 (fr) *	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
US5898032A (en) *	1997-06-23	1999-04-27	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
CA2348388A1 (en) *	1998-08-17	2000-02-24	The State Of Oregon Acting By And Through The State Board Of Higher Educ Ation On Behalf Of The University Of Oregon	Gene regulating circadian clock function and photoperiodism

1995
- 1995-12-23 DE DE19549264A patent/DE19549264A1/de not_active Withdrawn
1996
- 1996-12-20 UA UA98074032A patent/UA59356C2/uk unknown
- 1996-12-20 AU AU19219/97A patent/AU716249B2/en not_active Ceased
- 1996-12-20 DE DE59610600T patent/DE59610600D1/de not_active Expired - Lifetime
- 1996-12-20 CA CA002241192A patent/CA2241192A1/en not_active Abandoned
- 1996-12-20 PL PL96327182A patent/PL187180B1/pl not_active IP Right Cessation
- 1996-12-20 KR KR1019980704797A patent/KR19990076685A/ko not_active Ceased
- 1996-12-20 IL IL12447296A patent/IL124472A/en not_active IP Right Cessation
- 1996-12-20 AT AT96946221T patent/ATE244567T1/de not_active IP Right Cessation
- 1996-12-20 WO PCT/DE1996/002486 patent/WO1997023228A2/de not_active Ceased
- 1996-12-20 BR BR9612207A patent/BR9612207A/pt not_active Application Discontinuation
- 1996-12-20 PT PT96946221T patent/PT868188E/pt unknown
- 1996-12-20 NZ NZ330741A patent/NZ330741A/xx unknown
- 1996-12-20 SK SK792-98A patent/SK79298A3/sk unknown
- 1996-12-20 DK DK96946221T patent/DK0868188T3/da active
- 1996-12-20 US US09/091,665 patent/US6995149B1/en not_active Expired - Fee Related
- 1996-12-20 JP JP9523223A patent/JP2000502108A/ja active Pending
- 1996-12-20 HU HU9901662A patent/HUP9901662A3/hu unknown
- 1996-12-20 ES ES96946221T patent/ES2202498T3/es not_active Expired - Lifetime
- 1996-12-20 EP EP96946221A patent/EP0868188B1/de not_active Expired - Lifetime
- 1996-12-20 CZ CZ19982000A patent/CZ291743B6/cs not_active IP Right Cessation
1998
- 1998-05-22 IS IS4753A patent/IS4753A/is unknown
- 1998-06-03 MX MX9804395A patent/MX9804395A/es not_active IP Right Cessation
- 1998-06-22 NO NO982902A patent/NO982902L/no unknown

Also Published As

Publication number	Publication date
PL187180B1 (pl)	2004-05-31
DE59610600D1 (de)	2003-08-14
IL124472A (en)	2001-07-24
WO1997023228A3 (de)	1997-08-28
EP0868188A2 (de)	1998-10-07
BR9612207A (pt)	1999-07-13
AU716249B2 (en)	2000-02-24
IS4753A (is)	1998-05-22
PL327182A1 (en)	1998-11-23
EP0868188B1 (de)	2003-07-09
JP2000502108A (ja)	2000-02-22
KR19990076685A (ko)	1999-10-15
HUP9901662A2 (hu)	1999-09-28
NZ330741A (en)	2000-03-27
MX9804395A (es)	1998-09-30
DK0868188T3 (da)	2003-10-06
PT868188E (pt)	2003-11-28
AU1921997A (en)	1997-07-17
DE19549264A1 (de)	1997-06-26
WO1997023228A2 (de)	1997-07-03
CZ291743B6 (cs)	2003-05-14
IL124472A0 (en)	1998-12-06
CZ9802000A3 (cs)	1998-11-11
HUP9901662A3 (en)	1999-11-29
US6995149B1 (en)	2006-02-07
NO982902D0 (no)	1998-06-22
NO982902L (no)	1998-06-22
CA2241192A1 (en)	1997-07-03
ATE244567T1 (de)	2003-07-15
ES2202498T3 (es)	2004-04-01
UA59356C2 (uk)	2003-09-15

Publication	Publication Date	Title
US6995149B1 (en)	2006-02-07	Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen
US4544554A (en)	1985-10-01	Triphasic oral contraceptive
JP3020880B2 (ja)	2000-03-15	避妊のための多段階調剤
US4628051A (en)	1986-12-09	Triphasic oral contraceptive
US4616006A (en)	1986-10-07	Triphasic oral contraceptive
FI103951B (fi)	1999-10-29	Ehkäisyjärjestelmä
AU710819B2 (en)	1999-09-30	Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
EP0912186B1 (en)	2002-03-06	Progestogen-anti-progestogen regimens
US6506390B2 (en)	2003-01-14	Progestogen-anti-progestogen regimens
CZ420597A3 (cs)	1998-03-18	Farmaceutický kombinovaný preparát, souprava a způsob pro hormonální antikoncepci
AU726091B2 (en)	2000-11-02	Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
SK124396A3 (en)	1997-05-07	Combined hormonal contraception pharmaceutical preparation
US20100168071A1 (en)	2010-07-01	Extended estrogen dosing contraceptive regimen
US6642219B1 (en)	2003-11-04	Progestogen-antiprogestogen regimens
WO1999051214A2 (en)	1999-10-14	Progestogen-only contraceptive kit
HK1077743A1 (zh)	2006-02-24	避孕组合物
HK1077743B (en)	2009-04-24	Composition for contraception